Martine Piccart

114.7k total citations · 20 hit papers
836 papers, 42.9k citations indexed

About

Martine Piccart is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Martine Piccart has authored 836 papers receiving a total of 42.9k indexed citations (citations by other indexed papers that have themselves been cited), including 627 papers in Oncology, 352 papers in Cancer Research and 229 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Martine Piccart's work include HER2/EGFR in Cancer Research (333 papers), Breast Cancer Treatment Studies (293 papers) and Cancer Treatment and Pharmacology (258 papers). Martine Piccart is often cited by papers focused on HER2/EGFR in Cancer Research (333 papers), Breast Cancer Treatment Studies (293 papers) and Cancer Treatment and Pharmacology (258 papers). Martine Piccart collaborates with scholars based in Belgium, United States and Italy. Martine Piccart's co-authors include Christos Sotiriou, Evandro de Azambuja, Sherene Loi, Fátima Cardoso, Denis Larsimont, Christine Desmedt, Angelo Di Leo, Dimitrios Zardavas, Benjamin Haibe‐Kains and Giuseppe Viale and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Martine Piccart

806 papers receiving 41.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis

2006 1.5k citations Christos Sotiriou, Sherene Loi et al. JNCI Journal of the National Cancer Institute profile →
Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98

2013 1.2k citations Sherene Loi, Nicolas Sirtaine et al. Journal of Clinical Oncology profile →
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

2014 956 citations Sherene Loi, Stefan Michiels et al. profile →
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

2017 918 citations Evandro de Azambuja, Dimitrios Zardavas et al. profile →
Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer

2006 842 citations Sherene Loi, Giuseppe Viale et al. JNCI Journal of the National Cancer Institute profile →
Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17

2005 818 citations Martine Piccart, Kathleen I. Pritchard et al. JNCI Journal of the National Cancer Institute profile →
Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series

2007 726 citations Fanny Piette, Sherene Loi et al. Clinical Cancer Research profile →
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

2017 688 citations David Cameron, Martine Piccart et al. profile →
Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures

2008 654 citations Christos Sotiriou, Benjamin Haibe‐Kains et al. profile →
Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes

2008 601 citations Benjamin Haibe‐Kains, Denis Larsimont et al. Clinical Cancer Research profile →
Definition of Clinically Distinct Molecular Subtypes in Estrogen Receptor–Positive Breast Carcinomas Through Genomic Grade

2007 599 citations Sherene Loi, Benjamin Haibe‐Kains et al. Journal of Clinical Oncology profile →
A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)

2015 533 citations Martine Piccart et al. profile →
Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019

2019 438 citations Michael Gnant, Marco Colleoni et al. profile →
Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab

2015 432 citations Roberto Salgado, Evandro de Azambuja et al. profile →
Clinical management of breast cancer heterogeneity

2015 426 citations Dimitrios Zardavas, Martine Piccart et al. profile →
Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2

2014 407 citations Martine Piccart, Gabriel N. Hortobágyi et al. profile →
Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis

2013 383 citations Shinzaburo Noguchi, Kathleen I. Pritchard et al. profile →
ESMO-Magnitude of Clinical Benefit Scale version 1.1

2017 369 citations Jan Bogaerts, Martine Piccart et al. profile →
Immunotherapy in breast cancer: an overview of current strategies and perspectives

2023 202 citations Véronique Debien, Martine Piccart et al. npj Breast Cancer profile →
Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression

2024 71 citations Hope S. Rugo, Kevin Punie et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Martine Piccart

Since Specialization

Citations

This map shows the geographic impact of Martine Piccart's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martine Piccart with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martine Piccart more than expected).

Fields of papers citing papers by Martine Piccart

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martine Piccart. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martine Piccart. The network helps show where Martine Piccart may publish in the future.

Co-authorship network of co-authors of Martine Piccart

This figure shows the co-authorship network connecting the top 25 collaborators of Martine Piccart. A scholar is included among the top collaborators of Martine Piccart based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martine Piccart. Martine Piccart is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	2O TILs and PD-L1 early dynamics in the randomized Neo-CheckRay phase II trial evaluating neo-adjuvant immuno-radiation and adenosine pathway blockade for early-stage, high risk ER+/HER2- breast cancer (BC) 2024 ·Immuno-Oncology Technology ·(unknown), (unknown), (unknown), (unknown), Isabelle Desmoulins, Emanuela Romano, Vincent Remouchamps, (unknown), (unknown), Cédric van Marcke, (unknown), Michail Ignatiadis, Martine Piccart, Denis Larsimont, John Stagg, Christos Sotiriou, Roberto Salgado, Laurence Buisseret	0
2	PIK3CAcopy-number gain and inhibitors of the PI3K/AKT/mTOR pathway in triple-negative breast cancer 2023 ·Molecular Case Studies ·Ottavia Amato, Laurence Buisseret, Géraldine Gebhart, (unknown), Denis Larsimont, Ahmad Awada, Martine Piccart, Philippe Aftimos	5
3	Tailoring the optimal duration of the extended adjuvant endocrine therapy in patients with early-stage breast cancer. A systematic review and meta-analysis of randomized clinical trials 2023 ·The Breast ·Laura Pala, Tommaso De Pas, Eleonora Pagan, (unknown), Chiara Catania, Emma Zattarin, Paolo Arnone, Massimo Maria Grassi, Marco Colleoni, Antonio C. Wolff, Javier Cortés, Martine Piccart, Richard D. Gelber, Giuseppe Viale, Vincenzo Bagnardi, Fabio Conforti	1
4	Immune response to anti-SARS-CoV-2 prime-vaccination in patients with cancer: a systematic review and meta-analysis 2022 ·Journal of Cancer Research and Clinical Oncology ·Diogo Martins-Branco, Guilherme Nader Marta, (unknown), Véronique Debien, Lieveke Ameye, Mariana Brandão, Kevin Punie, Angela Loizidou, Karen Willard‐Gallo, (unknown), Ahmad Awada, Martine Piccart, Evandro de Azambuja	9
5	FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer 2021 ·npj Breast Cancer ·Andrea Gombos, David Venet, Lieveke Ameye, Peter Vuylsteke, Patrick Neven, Vincent R. Richard, François P. Duhoux, Jean‐François Laes, Françoise Rothé, Christos Sotiriou, Marianne Paesmans, Ahmad Awada, Thomas Guiot, Patrick Flamen, Martine Piccart, Michail Ignatiadis, Géraldine Gebhart	14
6	ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor–Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials 2020 ·Clinical Cancer Research ·Nicholas C. Turner, Claire Swift, Lucy Kilburn, Charlotte Fribbens, Matthew Beaney, Isaac García-Murillas, Aman U. Budzar, J.F.R. Robertson, William J. Gradishar, Martine Piccart, Gaia Schiavon, Judith M. Bliss, Mitch Dowsett, Stephen Johnston, Stephen Chia	100
7	ecancermedicalscience 2016 ·ecancermedicalscience ·Ana Catarina Pinto, Fernando Ferreira‐Santos, (unknown), Evandro de Azambuja, Francisco Pimentel, Martine Piccart, Darius Razavi	16
8	ecancermedicalscience 2016 ·ecancermedicalscience ·Martine Piccart, Giulia Viale, Peter Ellis, Marc Abramowicz, Lisa A. Carey	6
9	The Prognostic Role of Androgen Receptor in Patients with Early-Stage Breast Cancer: A Meta-analysis of Clinical and Gene Expression Data 2016 ·Clinical Cancer Research ·Ivana Božović‐Spasojević, Dimitrios Zardavas, Sylvain Brohée, Lieveke Ameye, Debora Fumagalli, Felipe Ades, Evandro de Azambuja, Yacine Barèche, Martine Piccart, Marianne Paesmans, Christos Sotiriou	84
10	Luminal B Breast Cancer: Molecular Characterization, Clinical Management, and Future Perspectives 2014 ·Journal of Clinical Oncology ·Felipe Ades, Dimitrios Zardavas, Ivana Božović‐Spasojević, Lina Pugliano, Debora Fumagalli, Evandro de Azambuja, Giuseppe Viale, Christos Sotiriou, Martine Piccart	292
11	Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2 2013 ·JNCI Journal of the National Cancer Institute ·Michael Gnant, José Baselga, Hope S. Rugo, Shinzaburo Noguchi, Howard A. Burris, Martine Piccart, Gabriel N. Hortobágyi, Janice F. Eakle, Hirofumi Mukai, Hiroji Iwata, Matthias Geberth, Lowell L. Hart, Peyman Hadji, Mona El-Hashimy, (unknown), Tetiana Taran, Tarek Sahmoud, David Lebwohl, Mario Campone, Kathleen I. Pritchard	77
12	Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98 breakdown → 2013 ·Journal of Clinical Oncology ·Sherene Loi, Nicolas Sirtaine, Fanny Piette, Roberto Salgado, Giuseppe Viale, (unknown), Ghizlane Rouas, Prudence A. Francis, John Crown, Erika Hitre, Evandro de Azambuja, Emmanuel Quinaux, Angelo Di Leo, Stefan Michiels, Martine Piccart, Christos Sotiriou	1213
13	Elucidating Prognosis and Biology of Breast Cancer Arising in Young Women Using Gene Expression Profiling 2012 ·Clinical Cancer Research ·Hatem A. Azim, Stefan Michiels, Philippe L. Bédard, Sandeep K. Singhal, Carmen Criscitiello, Michail Ignatiadis, Benjamin Haibe‐Kains, Martine Piccart, Christos Sotiriou, Sherene Loi	278
14	Class III β-Tubulin Isotype Predicts Response in Advanced Breast Cancer Patients Randomly Treated Either with Single-Agent Doxorubicin or Docetaxel 2008 ·Clinical Cancer Research ·Carlos M. Galmarini, Isabelle Treilleux, Fátima Cardoso, Chantal Bernard-Marty, Virginie Durbecq, David Gancberg, Marie-Christine Bissery, Marianne Paesmans, Denis Larsimont, Martine Piccart, Angelo Di Leo, Charles Dumontet	55
15	Phase III Study Comparing Exemestane With Tamoxifen As First-Line Hormonal Treatment of Metastatic Breast Cancer in Postmenopausal Women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group 2008 ·Journal of Clinical Oncology ·Robert Paridaens, Luc Dirix, L.V.A.M. Beex, M. Nooij, David Cameron, Tanja Čufer, Martine Piccart, Jan Bogaerts, Patrick Therasse	228
16	[The new generation of breast cancer clinical trials: the right drug for the right target]. 2008 ·PubMed ·Evandro de Azambuja, Fátima Cardoso, (unknown), Carolyn Straehle, Stella Dolci, K. Vantongelen, Martine Piccart	11
17	Long-term survival in pituitary metastasis from breast cancer 2005 ·The Breast ·Evandro de Azambuja, Martine Piccart, Ahmad Awada	5
18	HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. 2002 ·PubMed ·Angelo Di Leo, David Gancberg, Denis Larsimont, Minna Tanner, Tero A.H. Järvinen, Ghizlane Rouas, Stella Dolci, Jean-Yves Leroy, Marianne Paesmans, Jorma Isola, Martine Piccart	216
19	HER-2/neu evaluation by immunohistochemistry and fluorescence in situ hybridization in breast cancer: implications for daily laboratory practice. 2002 ·PubMed ·Denis Larsimont, Angelo Di Leo, Ghizlane Rouas, Marianne Paesmans, (unknown), Chantal Bernard, Fátima Cardoso, Alain Verhest, Martine Piccart, David Gancberg	11
20	Actualités thérapeutiques dans le cancer du sein 2000 ·Bulletin du Cancer ·Ahmad Awada, Angelo Di Leo, Martine Piccart	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact